A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of [14C] BMS-986166 in Healthy Male Participants
Latest Information Update: 24 Mar 2023
At a glance
- Drugs BMS 986166 (Primary) ; Bisacodyl
- Indications Atopic dermatitis; Encephalitis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 20 Mar 2023 Status changed from not yet recruiting to completed.
- 13 Jun 2022 New trial record